Age at onset | 64 | 66 | 72 | 77 | 80 | 70 | 61 | 78 | 59 | 69 | 64 | 75 | 75 | 59 |
Sex | M | F | F | M | M | M | F | F | F | M | M | M | F | F |
Duration of disease (years) | 5 | 17 | 1 | 6 | 1 | 10 | 15 | 3 | 5 | 20 | 11 | 3.3 | 9 | 43 |
Duration of treatment at onset of neuropathy (months) | 10 | 19.1 | 1.7 | 19 | 3.2 | 1 | 12 | 0.6 | 29 | 2 | 5 | 2 | 24 | 17 |
Neurological status before leflunomide | Normal | Normal | Normal | Normal | Dysaesthesia | Normal | Normal | Hypoaesthesia | Normal | Normal | Normal | Dysaesthesia | Normal | Normal |
Diabetes mellitus | No | No | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | No |
No previous or concomitant neurotoxic drug | – | – | – | – | – | Almitrine | – | – | – | Atorvastatine | – | Thalidomide | – | – |
CNS | SAN | MSAN | SAN | MSAN | MSAN | SAN | SAN | MSAN | SAN | SAN | SAN | SAN | SAN | SAN |
pANCA | Yes | No | No | No | Yes | No | No | No | Un | Un | No | Yes | No | No |
Concomitant drugs | 1, 3, 4, 8 | 1, 2, 3, 5, 8 | 5, 6 | 1, 3, 4, 7 | 1, 4, 5 | 1, 2, 4, 5 | 1, 2, 3, 8, 9 | 1, 2 | 1, 2, 4, 5 | 1, 4 | 1, 2, 4, 6 | 1, 3, 4, 5, 8 | 2, 3, 4 | 2, 3, 4 |
Washout* | Yes | No | No | No | No | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes |
Outcome after stopping drug | Stabilisation | Recovery | Improvement | Stabilisation | Stabilisation | Improvement | Improvement | Stabilisation | Improvement | Stabilisation | Stabilisation | Improvement | Continuing | Improvement |